CORE--SYNTHETIC ORGANIC CHEMISTRY FACILITY

$156,818P01FY2000ESNIH

Univ Of Med/Dent Nj-R W Johnson Med Sch, Piscataway NJ

Investigators

Linked publications & trials

Paper 17910028 Paper 17786932 Paper 17229725 Paper 16889770 Paper 16259964 Paper 16079130 Paper 15691590 Paper 15064226 Paper 15020191 Paper 14644624 Paper 14550746 Paper 12855403 Paper 12845232 Paper 12842828 Paper 12730222 Paper 12730217 Paper 12650610 Paper 12529435 Paper 12417260 Paper 12392966 Paper 12392965 Paper 12392718 Paper 12225989 Paper 12204102 Paper 12162464 Paper 12093477 Paper 12051994 Paper 12050186 Paper 11981759 Paper 11968013 Paper 11964409 Paper 11930008 Paper 11919077 Paper 11918223 Paper 11888198 Paper 11880315 Paper 11857454 Paper 11854223 Paper 11765017 Paper 11764933 Paper 11754871 Paper 11749118 Paper 11739560 Paper 11691625 Paper 11606063 Paper 11493607 Paper 11396480 Paper 11377388 Paper 11342566 Paper 11315992 Paper 11278791 Paper 11264022 Paper 11263772 Paper 11246131 Paper 11181551 Paper 11157060 Paper 11141054 Paper 11134540 Paper 11086947 Paper 11073098 Paper 10860539 Paper 10857758 Paper 10683266

Abstract

The role of the Synthetic Organic Chemistry Core is to provide candidate pharmaceuticals both as probes of N0S and as potential therapeutic agents. This core facility will support the individual projects by synthesizing three classes of agents: 1) novel, rationally- designed guanidine mimics as candidate N0S inhibitors; 2) new aza- heterocyclic probes of the N0S heme site and computational support to understand their modes of action; and, 3) N0-releasing candidate depot polymers based on bio-compatible macromolecular carriers.

View original record on NIH RePORTER →